ANNEXON INC (ANNX) competitors & alternatives
Health Care · NASDAQ
ANNEXON INC (ANNX)'s top competitors and alternatives — its most similar public companies — include BIOCRYST PHARMACEUTICALS INC (BCRX), Alnylam Pharmaceuticals (ALNY), IMMUNOVANT INC (IMVT), REZOLUTE INC (RZLT), ELEDON PHARMACEUTICALS INC (ELDN), BridgeBio Oncology Therapeutics, Inc. (BBOT), ZURA BIO LTD CLASS A (ZURA), MONOPAR THERAPEUTICS INC (MNPR), Odyssey Therapeutics, Inc. (ODTX), DESIGN THERAPEUTICS INC (DSGN), CLIMB BIO INC (CLYM) and UPSTREAM BIO INC (UPB). These are ANNEXON INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ANNX competitors & alternatives
-
BIOCRYST PHARMACEUTICALS INCBCRXHealth Care
BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases…
$9.51 (as of 2026-07-22) · market cap $2.4B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
IMMUNOVANT INCIMVTHealth Care
Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by…
$39.05 (as of 2026-07-22) · market cap $8.0B
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
ZURA BIO LTD CLASS AZURAHealth Care
Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current…
$5.40 (as of 2026-07-22) · market cap $532M
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$112.48 (as of 2026-07-22) · market cap $752M
-
Odyssey Therapeutics, Inc.ODTXHealth Care
A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
$18.61 (as of 2026-07-22) · market cap $865M
-
DESIGN THERAPEUTICS INCDSGNHealth Care
A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene…
$11.78 (as of 2026-07-22) · market cap $736M
-
CLIMB BIO INCCLYMHealth Care
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and…
$12.58 (as of 2026-07-22) · market cap $720M
-
UPSTREAM BIO INCUPBHealth Care
Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of…
$6.59 (as of 2026-07-22) · market cap $376M
Not quite? Describe exactly what you want →
Peers are ANNEXON INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ANNEXON INC (ANNX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.